Anti-CD55 (Extracellular region) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, IHC |
|---|---|
| Primary Accession | P08174 |
| Host | Mouse |
| Clonality | Mouse Monoclonal |
| Isotype | IgG2a |
| Clone Names | M002 |
| Calculated MW | 41400 Da |
| Gene ID | 1604 |
|---|---|
| Other Names | Complement decay-accelerating factor, DAF, CD_antigen, CD55, CR |
| Target/Specificity | CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients. |
| Dilution | WB~~1:1000 IHC~~1:100~500 |
| Format | Protein G Purified |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | Anti-CD55 (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Shipping | Blue Ice |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.


